Journal article

Genomic and clinical predictors of lacosamide response in refractory epilepsies

Sinead B Heavin, Mark McCormack, Stefan Wolking, Lisa Slattery, Nicole Walley, Andreja Avbersek, Jan Novy, Saurabh R Sinha, Rod Radtke, Colin Doherty, Pauls Auce, John Craig, Michael R Johnson, Bobby PC Koeleman, Roland Krause, Wolfram S Kunz, Anthony G Marson, Terence JO Brien, Josemir W Sander, Graeme J Sills Show all

Epilepsia Open | WILEY | Published : 2019


Objective: Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real-world clinical setting. Methods: We tested the association of clinical predictors with treatment response using regression modeling in a cohort of people with refractory epilepsy. Genetic assessment for lacosamide response was conducted via genome-wide association studies and exome studies, comprising 281 candidate genes. Results: Most patients (479/483) were treated with LCM in addition to other AEDs. Our results corroborate previous findings that patients with refractory genetic generalized epilepsy (GGE) may respond to treatment ..

View full abstract


Awarded by Marie-Curie Individual Fellowship, European Commission

Awarded by Science Foundation Ireland

Awarded by FP7 Health

Awarded by Clinician Scientist Program of the Medical Faculty of the University of Tubingen

Funding Acknowledgements

Marie-Curie Individual Fellowship, European Commission, Grant/Award Number: 751761; Science Foundation Ireland, Grant/Award Number: 13/CDA/2223 and 16/RC/3948; FP7 Health, Grant/Award Number: 279062 "EpiPGX"; UK Department of Health's Biomedical Research Centres'; Dr Marvin Weil Epilepsy Research Fund; Clinician Scientist Program of the Medical Faculty of the University of Tubingen, Grant/Award Number: 418-0-0